冻干人纤维蛋白胶在心血管外科手术中的应用

The clinical use of fibrin sealant in cardiovascular surgery

目的：评价冻干人纤维蛋白胶在心外科手术应用中的止血效果及安全性。方法：选取年龄为18～60岁,体外循环下行心脏直视手术,并有主动脉或右心室切口的病人共60例。随机分为试验组和对照组各30例,选择主动脉或右心室缝合后有渗血的切口为试验创面,局部使用试验药或对照药。以止血时间及出血量为主要疗效评价指标,比较试验药和对照药的临床疗效。试验组患者随机抽取7例进行3个月安全性随访。结果：用药前后生命体征变化及实验室检查结果的变化,两组之间无明显差异；试验组止血时间(14．67±6．18s)和渗血量(0．81±0．54g)等指标均明显优于对照组(分别为250．45±37．02s和15．39±2．69g)；7例试验组病例术后3个月的安全性随访结果均为阴性。结论：冻干人纤维蛋白胶对心脏外科手术后的切口及创面渗血具有良好的止血和组织粘合作用,且具有可靠的病毒安全性。

Objective： To assess the hemostatic effect and security of fibrin sealant in cardiovascular surgery. Methods： 60 patients who were performed open-heart operations with incisions on aorta or right ventricle were divided randomly into test group or co trol group. Each group contains 30 patients. FS（test group） or NS（control group） were local used on the incisions in these patients. The hemostatic time and bleeding quantity were used as main evaluating indicators. 7 patients of test group underwent 3 months followup for the security. Results ： The hemostatic time （ 14.67±6.18 s） and bleeding quantity （0.81±0.54g） of test group were obviously better than control group（ 250.45±37.02s and 15.39±2.69g）. Conclusion： Fibrin sealant has good effects of hemostasis and tissue conglutination in cardiovascular surgery.